Siensmetrica Adds New Advisory Board Members

Dr. Eva Redei and Dr. Jeremy Worley join advisory board to deepen company’s expertise in evaluating biomedical research

October 1, 2025 — Siensmetrica today announced the appointment of two distinguished scientists, Dr. Eva E. Redei and Dr. Jeremy Worley, to the company’s advisory board.

Siensmetrica’s mission is to enable medical professionals to quickly identify and utilize high-quality research. While the advisory board has deep expertise from the clinical perspective, the additions of Dr. Redei and Dr. Worley bring an invaluable researcher’s viewpoint, strengthening the orgainzation’s ability to evaluate the quality, clarity, and scientific soundness of bio-medical research.

About the Board Members

Eva E. Redei, MS, PhD
Dr. Redei is a Professor Emeritus in Psychiatry and Behavioral Sciences at Northwestern University’s Feinberg School of Medicine. With over 150 publications and 15 patents, her extensive career has focused on identifying biomarkers for depressive disorders. Her experience serving on NIH review panels and the editorial boards of prestigious journals like Molecular Psychiatry gives her an unparalleled understanding of what constitutes rigorous, impactful research.

Dr. Jeremy Worley, PhD
Dr. Worley is an Assistant Professor in Systems Biology at Columbia University Irving Medical Center and a Chan Zuckerberg Biohub New York investigator. His work at the forefront of computational biology and CRISPR-based genome engineering provides critical insight into the modern tools and methodologies driving today’s most advanced research. Dr. Worley’s experience in both academic and private sector settings is directly relevant to our work at the intersection of science and technology.

“The addition of these two accomplished researchers ensures that our Tessa software platform is built on a comprehensive understanding of the entire research ecosystem from lab to clinic,” Siensmetrica CEO, Marc Toth said. “Their guidance will be instrumental as we continue to refine our methodologies for scoring and surfacing the most credible and significant biomedical studies.”

About Siensmetrica

Siensmetrica’s mission is to help medical professionals deliver better care and improve outcomes by quickly and easily identifying high quality, trustworthy scientific information. The company’s Tessa platform uses a framework—Transparency, Explainability, and Significance or “T.E.S.”— that taps same sort of reasoning heuristics humans do to analyze and assess the quality of bio-medical research. Tessa evaluates nearly 200 variables within research to derive a clear overall score, five sub-scores, and detailed explanations that make it simple to quickly differentiate high quality, trustworthy material from inferior product. For more information, visit the Siensmetrica website at www.siensmetrica.com or via email at info@siensmetrica.com.

###

Media contact:
A. Sage Osterfeld
press@siensmetrica.com